<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04985110</url>
  </required_header>
  <id_info>
    <org_study_id>21-02-0154</org_study_id>
    <nct_id>NCT04985110</nct_id>
  </id_info>
  <brief_title>Administration of Antibiotic Prophylaxis for Transperineal Prostate Biopsy in Cipto Mangunkusumo Hospital</brief_title>
  <official_title>Pemberian Antibiotik Profilaksis Pada Biopsi Prostat Transperineal di RSUPN Dr. Cipto Mangunkusumo: Uji Klinis Acak Terkontrol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial aims to compare the rate of perioperative infection&#xD;
      complications in transperineal prostate biopsy between the group that receives prophylactic&#xD;
      antibiotic and the group that receives placebo. The types of infection studied included&#xD;
      bacteriuria, urinary tract infection (UTI), UTI with fever (febrile UTI), and sepsis. This&#xD;
      study hypothesized that the administration of prophylactic antibiotics during transperineal&#xD;
      prostate biopsy would result in lower rates of perioperative infection complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate cancer screenings will be conducted in all patients aged &gt;45 years with lower&#xD;
      urinary tract symptoms (LUTS) through PSA test and digital rectal examination (DRE). Those&#xD;
      with PSA levels of 4.0 ng/mL or higher or other abnormal findings on DRE will be recommended&#xD;
      to undergo transperineal prostate biopsy. In addition, participants will be offered to&#xD;
      participate in this clinical trial, in which participants will be randomly assigned into two&#xD;
      groups: one group will receive prophylactic antibiotic, while the other group will receive&#xD;
      placebo.&#xD;
&#xD;
      The randomization process will be conducted before the biopsy procedure. Computers will&#xD;
      generate random numbers, which will put the participants into two groups. These numbers can&#xD;
      only be accessed by the research monitor (Clinical Research Supporting Unit of IMERI FMUI),&#xD;
      while the investigators, surgeons, residents, and nurses involved will be blinded to this&#xD;
      information. To ensure patient blinding, the placebo and cotrimoxazole forte 960 mg will be&#xD;
      reformed as identical as possible in capsule preparation.&#xD;
&#xD;
      The primary outcomes of this clinical trial are the rate of perioperative infection&#xD;
      complications, including bacteriuria, urinary tract infection (UTI), UTI with fever (febrile&#xD;
      UTI), and sepsis, in 24 hours, 7 days, and 14 days postoperatively. The secondary outcomes of&#xD;
      this clinical trial are the rate of readmission.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2021</start_date>
  <completion_date type="Anticipated">July 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 6, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This randomized controlled trial aims to compare the rate of perioperative infection complications in transperineal prostate biopsy between the group that receives prophylactic antibiotic and the group that receives placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The randomization process will be conducted before the study started. Computers will generate random numbers, which will put the participants into two groups. These numbers can only be accessed by the clinical research supporting unit team, while the investigators, surgeons, residents, nurses, and pharmacologists involved will be blinded to this information. To ensure patient blinding, the placebo will be manufactured as identical capsules.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of infection complications</measure>
    <time_frame>24 hours</time_frame>
    <description>The rate of infection complications, including bacteriuria, urinary tract infection (UTI), UTI with fever (febrile UTI), and sepsis, will be measured in both treatment and placebo groups in 24 hours postoperatively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of infection complications</measure>
    <time_frame>7 days</time_frame>
    <description>The rate of infection complications, including bacteriuria, urinary tract infection (UTI), UTI with fever (febrile UTI), and sepsis, will be measured in both treatment and placebo groups in 7 days postoperatively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of infection complications</measure>
    <time_frame>14 days</time_frame>
    <description>The rate of infection complications, including bacteriuria, urinary tract infection (UTI), UTI with fever (febrile UTI), and sepsis, will be measured in both treatment and placebo groups in 14 days postoperatively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of readmission</measure>
    <time_frame>7 days</time_frame>
    <description>The rate of readmission will also be assessed in 7 days postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of readmission</measure>
    <time_frame>14 days</time_frame>
    <description>The rate of readmission will also be assessed in 14 days postoperatively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostate Biopsy</condition>
  <condition>Perioperative Complication</condition>
  <condition>Bacteriuria</condition>
  <condition>Urinary Tract Infections</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Cotrimoxazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment group will receive Cotrimoxazole Forte 960 mg PO q.d. 4 hours before the biopsy procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo group will receive placebo q.d. 4 hours before the biopsy procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cotrimoxazole</intervention_name>
    <description>The treatment group will receive Cotrimoxazole Forte 960 mg PO q.d. 4 hours before the biopsy procedure.</description>
    <arm_group_label>Cotrimoxazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo group will receive placebo q.d. 4 hours before the biopsy procedure.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with lower urinary tract symptoms aged &gt;45 years with either PSA levels of 4.0&#xD;
             ng/mL or higher or abnormal findings on digital rectal examination (DRE)&#xD;
&#xD;
          -  Patient with a negative initial urine culture / urinalysis test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refuses to undergo transperineal prostate biopsy&#xD;
&#xD;
          -  Patients who refuses to participate in the research&#xD;
&#xD;
          -  Patient who is unable to communicate effectively&#xD;
&#xD;
          -  Patient with a documented history of cotrimoxazole allergy&#xD;
&#xD;
          -  Patient who has consumed antibiotics for other indications prior to undergoing&#xD;
             prostate biopsy&#xD;
&#xD;
          -  Patient with urinary tract infection symptoms prior to undergoing prostate biopsy&#xD;
&#xD;
          -  Patient with a history of immunodeficiency disorders or long-term corticosteroid use&#xD;
&#xD;
          -  Patient with a history of prostate cancer&#xD;
&#xD;
          -  Patient with a history of prior prostate biopsy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agus Rizal A. H. Hamid, M.D, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitas Indonesia - Cipto Mangunkusumo Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harun Wijanarko Kusuma Putra, M.D, B.Med.Sci(Hons)</last_name>
    <role>Study Chair</role>
    <affiliation>Universitas Indonesia - Cipto Mangunkusumo Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Syamsu Hudaya, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Fatmawati General Hospital, Jakarta - Indonesia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hendy Mirza, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Persahabatan Central General Hospital, Jakarta - Indonesia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dyandra Parikesit, B.Med.Sc., M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Universitas Indonesia, Depok - Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Agus Rizal A. H. Hamid, MD, PhD</last_name>
    <phone>+628111803377</phone>
    <email>rizalhamid.urology@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harun Wijanarko Kusuma Putra, MD, B.Med.Sci(Hons)</last_name>
    <phone>+6281808912288</phone>
    <email>harun.wijanarko@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dr. Cipto Mangunkusumo Hospital</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agus Rizal AH Hamid, M.D., Ph.D.</last_name>
      <phone>+628111803377</phone>
      <email>rizalhamid.urology@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yasmina Zahra Syadza, M.D.</last_name>
      <phone>+6281314731670</phone>
      <email>syadza.yz@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>dr. Agus Rizal Ardy Hariandy Hamid, Sp.U(K), Ph.D</investigator_full_name>
    <investigator_title>Main Researcher</investigator_title>
  </responsible_party>
  <keyword>Antibiotic prophylaxis</keyword>
  <keyword>Transperineal prostate biopsy</keyword>
  <keyword>Randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Bacteriuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

